Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in the Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease.

Biotechnology

Larimar Therapeutics

Carole Ben-Maimon

Adrienne Clements-Egan

Gopi Shankar

Scott Straight

Michele Walsh

Matt Lynes

Kimberly Minger

Keith L.

Diana McCarson

Mohamed Hamdani

Noreen Scherer

Keith E. Lynch, Jr.

Jennifer Johansson

Michael Celano

The Research and Development team at Larimar Therapeutics is dedicated to advancing innovative therapies for complex rare diseases. Comprising scientists and clinical experts, the team focuses on the preclinical and clinical evaluation of their lead compound, CTI-1601, including conducting Phase 1 trials and ensuring regulatory compliance, while also exploring new research avenues to enhance treatment efficacy and patient outcomes.

Research and Development

Leadership Team

Finance and Administration

Research and Development

About

Team members

Other teams at Larimar Therapeutics

Leadership Team

Finance and Administration